2.40
2.40 (0%)
As of Aug 30, 2024
Arca Biopharma, Inc. [ABIO]
Source:
Company Overview
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (“PsO”)and other inflammatory and immunology (“I&I”) indications.
| Country | United States |
| Headquarters | westminster, colorado |
| Phone Number | (720) 940-2200 |
| Industry | manufacturing |
| CEO | Michael R. Bristow |
| Website | www.orukatx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-88.1 |
| Net Income | $-83.7 |
| Net Cash | $61.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -42.3% |
| Profit as % of Stockholder Equity | -21.9% |
Management Effectiveness
| Return on Equity | -21.9% |
| Return on Assets | -21.1% |
| Turnover Ratio | |
| EBITA | $-88.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $396 |
| Total Liabilities | $13.8 |
| Operating Cash Flow | $-57.8 |
| Investing Cash Flow | $-330.1 |
| Financing Cash Flow | $449.5 |
